Evolus(NASDAQ) EOLS

Evolus helps people look younger by reducing wrinkles. It sells beauty products to doctors for their patients. Consumers pay for these treatments with their own money.

What's in the Aesthetic Bag?

• Jeuveau: Purified botulinum toxin treatment for frown lines; also sold as Nuceiva outside the United States.
• Evolysse: Range of injectable facial gels for smoothing wrinkles and nasolabial folds.
• Service Revenue: Income generated from an agent relationship with a distribution partner in Canada.

Strategic Moves and Partnerships

• Partnered with Symatese to distribute five injectable gel product candidates in the United States.
• Launched two new facial gel products in the United States in April 2025.
• Modified a loan agreement with Pharmakon in May 2025 to increase available funding to $250 million.
• Entered a $30 million credit agreement with Eclipse Business Capital in March 2026.
• Settled litigation with Medytox, agreeing to pay royalties on toxin sales until September 2032.

The Evolus Edge

The company operates in the cash-pay market where patients pay doctors directly. This model avoids the need to deal with health insurance companies for payments.

Performance by the Numbers

• Net revenues reached $73.1 million in Q1 2026, up 6.7% from Q1 2025.
• Net loss narrowed to $10.7 million in Q1 2026, an improvement of 43.5% year-over-year.
• Operating loss improved to $6.8 million in Q1 2026, compared to a $15.2 million loss in Q1 2025.
• Gross profit was $48.9 million in Q1 2026, up from $46.7 million in the prior year.

The Final Word

Evolus has shifted from a single-product company to a broader aesthetics platform. Its expansion into facial fillers alongside its toxin product allows it to compete more effectively in the performance beauty market.